IMARC Group

Although it’s clear that the market for cold chain healthcare products are poised for robust growth, a strong and reliable cold chain logistics infrastructure will be critical for the sector’s development

With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate.

A new report from IMARC Group finds that one of the biggest advantages of biopharmaceuticals over conventional small molecule drugs is their high efficacy and target oriented nature.

A new report from IMARC Group suggests that an increased research and development into technologies that nullify the need of cold chains could restrain the growth of the global cold chain logistics industry.

Despite worldwide efforts to reduce the consumption of rare earth elements, IMARC Group expects strategies like substitution and recycling to have a little effect on their demand and dependability in the short term

A new report from IMARC Group expects a strong uptake of DPP-IV Inhibitors to drive sales in the Canadian Oral Antidiabetics market during 2011-2016.

A new report from IMARC Group expects a strong uptake of DPP-IV Inhibitors and other new drug classes to drive sales in the Turkish Oral Antidiabetics market during 2011-2016.

A new report from IMARC Group expects new drug launches to drive the growth of the Japanese Oral Antidiabetics market during 2011-2016.

A new report from IMARC Group expects the future growth of the NiMH battery market to be significantly impacted by a supply shortage of Neodymium

A new report from IMARC Group expects the strong growth of biopharmaceuticals and the launch of biosimilars to create huge opportunities for cold chain service providers